目的 探讨固本咳喘胶囊联合沙美特罗替卡松治疗支气管哮喘慢性持续期的临床疗效。方法 选取2022年5月—2024年12月安徽医科大学附属合肥医院收治的支气管哮喘慢性持续期患者126例，以随机数字表法分为对照组和治疗组，每组各63例。对照组吸入沙美特罗替卡松吸入粉雾剂，1吸/次，2次/d。治疗组在对照组基础上口服固本咳喘胶囊，1.2 g/次，3次/d。两组患者治疗3个月。观察两组患者临床疗效，比较治疗前后两组患者肺功能和免疫功能，血清炎症因子Toll样受体4（TLR4）、白细胞介素-17（IL-17）和C反应蛋白（CRP）水平，及哮喘控制测试评分（ACT）和哮喘生活质量调查问卷（AQLQ）评分。结果 治疗后，治疗组总有效率明显高于对照组（92.06% vs 77.78%，P＜0.05）。治疗后，两组患者的肺功能指标FEV1、FVC、PEF和FEV1/FVC水平较治疗前显著升高（P＜0.05），且治疗组患者肺功能水平明显高于对照组（P＜0.05）。治疗后，两组患者炎症因子TLR4、IL-17和CRP水平均显著降低（P＜0.05），且治疗组患者炎症因子水平明显低于对照组（P＜0.05）。治疗后，两组患者免疫功能指标外周血CD3⁺、CD4⁺、CD4⁺/CD8⁺较治疗前升高，而CD8⁺显著低于治疗前（P＜0.05），且治疗组患者免疫功能明显好于对照组（P＜0.05）。治疗后，两组ACT评分和AQLQ评分较治疗前显著升高（P＜0.05），且治疗组评分明显高于对照组（P＜0.05）。结论 固本咳喘胶囊联合沙美特罗替卡松治疗支气管哮喘慢性持续期的疗效显著，能显著改善肺功能，抑制炎症因子表达，提升免疫功能。

Objective To investigate the clinical efficacy of Guben Kechuan Capsules combined with salmeterol ticasone in treatment of chronic duration of bronchial asthma. Methods Patients (126 cases) with chronic duration of bronchial asthma in Hefei Hospital Affiliated to Anhui Medical University/The Second People’s Hospital of Hefei from May 2022 to December 2024 were divided into control group and treatment group by the random number table method, with 63 cases in each group. Patient in control group were administered with Salmeterol Xinafoate and Fluticasone Propionate Powder for inhalation, 1 inhalation/time, twice daily. Patient in treatment group were po administered with Guben Kechuan Capsules on the basis of the control group, 1.2 g/time, three times daily. Patient in two groups were treated for 3 months. After treatment, the clinical evaluations were evaluated, and the lung function and immune function, serum inflammatory factor TLR4, IL-17 and CRP levels, and the scores of ACT and AQLQ in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was significantly higher than that in the control group (92.06% vs 77.78%, P < 0.05). After treatment, the levels of lung function indicators FEV1, FVC, PEF and FEV1/FVC in two groups were significantly higher than those before treatment (P < 0.05), and the level of lung function in the treatment group was significantly higher than that in the control group (P < 0.05). After treatment, the levels of inflammatory factors TLR4, IL-17 and CRP in two groups were significantly reduced (P < 0.05), and the levels of inflammatory factors in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the immune function indicators of peripheral blood CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were increased compared with before treatment, while CD8⁺ was lower than before treatment (P < 0.05), and the immune function of the treatment group was significantly better than that of the control group (P< 0.05). After treatment, the ACT score and AQLQ score in two groups were significantly higher than those before treatment (P < 0.05), and the scores in the treatment group were significantly higher than that in control group (P < 0.05). Conclusion Guben Kechuan Capsules combined with salmeterol ticasone has significant efficacy in treatment of chronic duration of bronchial asthma, which can improve the lung function, reduce the level of serum inflammatory factors, improve the immune function of patients.

R974

合肥市卫生健康委应用医学研究项目（Hwk2022yb034）